These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 16671076)
1. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076 [TBL] [Abstract][Full Text] [Related]
2. Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV Mov Disord; 2007 Oct; 22(14):2037-42. PubMed ID: 17853463 [TBL] [Abstract][Full Text] [Related]
3. Depressive disorders and anti-parkinson drug treatment: a case register study. Brandt-Christensen M; Lopez AG; Nilsson FM; Andersen PK; Kessing LV Acta Psychiatr Scand; 2007 Jun; 115(6):466-72. PubMed ID: 17498158 [TBL] [Abstract][Full Text] [Related]
4. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs]. Martínez-Suárez MM; Blázquez-Menes B Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861 [TBL] [Abstract][Full Text] [Related]
5. Population prevalence and incidence of Parkinson's disease in an Australian community. Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942 [TBL] [Abstract][Full Text] [Related]
6. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Leoni O; Martignoni E; Cosentino M; Michielotto D; Calandrella D; Zangaglia R; Riboldazzi G; Oria C; Lecchini S; Nappi G; Frigo G Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):149-57. PubMed ID: 11998540 [TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and antidepressant drug treatment: a case-register study. Brandt-Christensen M; Garcia Lopez A; Mørkeberg Nilsson F; Kragh Andersen P; Vedel Kessing L Parkinsonism Relat Disord; 2007 Oct; 13(7):406-10. PubMed ID: 17369074 [TBL] [Abstract][Full Text] [Related]
8. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838 [TBL] [Abstract][Full Text] [Related]
9. Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. Trifirò G; Savica R; Morgante L; Vanacore N; Tari M; Moretti S; Galdo M; Spina E; Caputi AP; Arcoraci V Parkinsonism Relat Disord; 2008; 14(5):420-5. PubMed ID: 18316232 [TBL] [Abstract][Full Text] [Related]
10. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Brefel-Courbon C; Grolleau S; Thalamas C; Bourrel R; Allaria-Lapierre V; Loï R; Micallef-Roll J; Lapeyre-Mestre M Pain; 2009 Jan; 141(1-2):14-8. PubMed ID: 19062167 [TBL] [Abstract][Full Text] [Related]
11. Prediction model of Parkinson's disease based on antiparkinsonian drug claims. Moisan F; Gourlet V; Mazurie JL; Dupupet JL; Houssinot J; Goldberg M; Imbernon E; Tzourio C; Elbaz A Am J Epidemiol; 2011 Aug; 174(3):354-63. PubMed ID: 21606234 [TBL] [Abstract][Full Text] [Related]
12. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease]. Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809 [TBL] [Abstract][Full Text] [Related]
13. Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population. Chillag-Talmor O; Giladi N; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Peretz C J Parkinsons Dis; 2011; 1(1):35-47. PubMed ID: 23939255 [TBL] [Abstract][Full Text] [Related]
14. Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):781-3. PubMed ID: 16705201 [TBL] [Abstract][Full Text] [Related]
15. A national registry to determine the distribution and prevalence of Parkinson's disease in Thailand: implications of urbanization and pesticides as risk factors for Parkinson's disease. Bhidayasiri R; Wannachai N; Limpabandhu S; Choeytim S; Suchonwanich Y; Tananyakul S; Tharathep C; Panjapiyakul P; Srismith R; Chimabutra K; Phanthumchinda K; Asawavichienjinda T Neuroepidemiology; 2011; 37(3-4):222-30. PubMed ID: 22133707 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's prevalence estimated by a state registry. Strickland D; Bertoni JM Mov Disord; 2004 Mar; 19(3):318-23. PubMed ID: 15022187 [TBL] [Abstract][Full Text] [Related]
17. [The prevalence and pharmacological cost of Parkinson's disease in Spain]. Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323 [TBL] [Abstract][Full Text] [Related]
18. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs]. Artázcoz Sanz MT; Viñes Rueda JJ Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360 [TBL] [Abstract][Full Text] [Related]
19. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028 [TBL] [Abstract][Full Text] [Related]
20. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Tandberg E; Larsen JP; Nessler EG; Riise T; Aarli JA Mov Disord; 1995 Sep; 10(5):541-9. PubMed ID: 8552103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]